PetVivo Holdings, Inc. (PETV)

Market Cap	32.92M
Revenue (ttm)	847,023
Net Income (ttm)	-8.17M
Shares Out	10.83M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,862
Open	3.00
Previous Close	2.97
Day's Range	3.00 - 3.07
52-Week Range	1.23 - 3.60
Beta	2.06
Analysts	Buy
Price Target	7.14 (+134.1%)
Earnings Date	Feb 9, 2023

About PETV

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 200...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Mr. John Lai
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: PETV

Financial Performance

In 2022, PETV's revenue was $115,586, an increase of 818.95% compared to the previous year's $12,578. Losses were -$5.01 million, 42.4% more than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for PETV stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 134.10% from the latest price.

Price Target

$7.14

(134.10% upside)

Analyst Consensus: Buy